Posted by Michael Wonder on 31 Mar 2017
pERC publishes initial recommendation for Roche's Gazyva
30 March 2017 - The outcome relates to the use of obinutuzumab in combination with chemotherapy followed by obinutuzumab monotherapy for the treatment of patients with follicular lymphoma who have relapsed after or are refractory to a rituximab containing regimen.
The pERC has recommended the reimbursement of obinutuzumab when used in combination with chemotherapy followed by obinutuzumab monotherapy conditional on uncertainty in the cost-effectiveness being reduced.
